Exhibit 99.2


Matritech Selects Cytogen to Market and Distribute New Point-of-Care Diagnostic
Test for Bladder Cancer in U.S.

-NMP22(R) BladderChek(TM) superior to current urine test, cytology, and returns
results during a patient's doctor office visit-

Newton, MA & Princeton, NJ (September 17, 2002) - Matritech Inc. (NASDAQ: NMPS)
and Cytogen Corporation (NASDAQ: CYTO) today announced that they have reached an
agreement in principle to enter into a five year agreement for Cytogen to be the
sole United States distributor for Matritech's NMP22(R) BladderChek(TM) test.
NMP22 BladderChek was recently approved by the U.S. Food and Drug Administration
as a point-of-care test for the management of patients with bladder cancer.
Pending approval and execution of a final agreement by both parties, Cytogen and
Matritech expect to have the product available to physicians during the next 30
days.

"Cytogen Corporation has a strong and established position in the urologic
oncology market and the ideal experience to distribute NMP22 BladderChek," said
David Corbet, president and chief operating officer of Matritech. "Their
in-house sales force has extensive experience selling comparable diagnostic
products to urologists in the United States, and we believe they will achieve
rapid market penetration for NMP22 BladderChek."

NMP22 BladderChek measures the level of NMP22, a specific marker associated with
bladder cancer and only the second tumor marker (in addition to prostate
specific antigen, or PSA) approved by the U.S. FDA and established in its
laboratory format for screening and monitoring cancer patients. The level of
NMP22 is often elevated in patients with bladder cancer, even at the earliest
stages of the disease. NMP22 BladderChek, which looks and works much like a home
pregnancy test, requires only a few drops of the patient's urine and typically
provides results in 30 minutes during a single office visit.

"The NMP22 BladderChek diagnostic test is a natural extension of our established
and growing product line in the diagnosis, staging and treatment of urologic
cancers," said H. Joseph Reiser, Ph.D., president and chief executive officer of
Cytogen Corporation. "In addition, since the urologist is the point of call, we
are able to leverage our existing sales force investment more effectively. We
are pleased to be associated with Matritech and NMP22, which helps identify
bladder cancer earlier and with greater ease and accuracy."

Clinical trial results show that NMP22 BladderChek detected four times more
early-stage bladder tumors and 2.5 times as many life threatening, high-grade
tumors as cytology, a widely-used bladder cancer urine test. It is expected that
NMP22 BladderChek will be used in conjunction with cystoscopy, a clinical
procedure that involves the use of a fiber optic tube inserted into the bladder
through the urethra to visually identify tumors.


"The market opportunity for NMP22 BladderChek has never been greater," said
Corbet. "The FDA has cleared the device for use in the United States, and
urologists at the most recent American Urological Association meeting expressed
tremendous interest in ordering the test. In addition, we have been experiencing
increasing sales and reorders in Europe, where our distributors are teaching
physicians about NMP22 BladderChek's clinical value. We are excited to work with
Cytogen, a focused and dedicated distribution partner for the United States
market."

Bladder cancer is the sixth most common cancer in the United States. Matritech
estimates that the total available U.S. urology market for the NMP22 tests is
2.7 million tests annually, representing an initial screening population of 1.2
million in addition to 1.5 million patients being monitored for recurrence after
treatment. The American Cancer Society estimates that in 2002 there will be
about 56,500 new cases of bladder cancer diagnosed in the United States (about
41,500 men and 15,000 women), and that 12,600 people (about 8,600 men and 4,000
women) will die from the disease.

Matritech's previous distribution agreement with Endocare Inc. of Irvine, Calif.
has been terminated by mutual agreement. Matritech signed a distribution
agreement in 2001 with TIMM Medical Technologies, which was subsequently
acquired in March of this year by Endocare.

About Matritech

Matritech is a leading developer of proteomics-based diagnostic products for the
early detection of cancer. Using its patented proteomics technology, Matritech
has identified proteins correlated with breast, bladder, prostate, cervical and
colon cancers. Matritech is one of the first companies to successfully employ
proteomics to create diagnostic products. The Company holds one of only two FDA
tumor marker approvals for the initial detection of cancer. The FDA-approved
NMP22 bladder cancer test is currently used by urologists. In addition, the
Company has a promising blood-based breast cancer test, NMP66, in clinical
trials. Initial research on a prostate cancer marker, NMP48, identified by
Matritech scientists shows the marker to be more accurate than the widely used
PSA test. NMP technology is licensed exclusively to Matritech from the
Massachusetts Institute of Technology.

About Cytogen
Cytogen Corporation of Princeton, NJ, is a biopharmaceutical company with an
established and growing product line in prostate cancer and other areas of
oncology. Currently marketed products include ProstaScint(R) (a monoclonal
antibody-based imaging agent used to image the extent and spread of prostate
cancer); BrachySeedTM I-125 and Pd-103 (two uniquely designed, next- generation
radioactive seed implants for the treatment of localized prostate cancer); and
Quadramet(R) (a skeletal targeting therapeutic radiopharmaceutical marketed for
the relief of bone pain in prostate and other types of cancer). Cytogen is
evolving a pipeline of oncology product candidates by developing its prostate
specific membrane antigen, or PSMA, technologies, which are exclusively licensed
from Memorial Sloan-Kettering Cancer Center. AxCell Biosciences of Newtown, PA,
a subsidiary of Cytogen Corporation, is engaged in the research and development
of novel biopharmaceutical products using its portfolio of functional proteomics
solutions and collection of proprietary signal transduction pathway information.
For more information, visit www.cytogen.com and www.axcellbio.com.




Statement Under the Private Securities Litigation Reform Act
Any forward-looking statements related to Matritech's or Cytogen's expectations
regarding their current and future products, regulatory approvals and expected
customer sales are subject to a number of risks and uncertainties, many of which
are beyond their control. These include but are not limited to, risks related to
unforeseen delays in, or denials of regulatory approvals, future product demand
and pricing, performance of distributors, competitive products and technical
developments, health care reform and general business and economic conditions.
There can be no assurance that Matritech's or Cytogen's expectations for their
products will be achieved.

###